

ABSTRACT

HLA-A*1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL
COMPOSITION COMPRISING THE SAME

5

The present invention relates to an HLA-A*1101-restricted
WT1 peptide, specifically, a peptide comprising an amino
acid sequence consisting of 9 contiguous amino acids from a
WT1 protein, wherein the peptide has an ability to bind to
10 an HLA-A*1101 molecule, and has an ability to induce a CTL.
The present invention also relates to a peptide dimer
having an ability to bind to an HLA-A*1101 molecule and
having an ability to induce a CTL, in which two peptide
monomers each comprising an amino acid sequence consisting
15 of 9 contiguous amino acids from a WT1 protein and
comprising at least one cysteine residue are bound to each
other through a disulfide bond. Furthermore, the present
invention relates to a polynucleotide encoding the peptide,
a pharmaceutical composition for the treatment and/or
20 prevention of a cancer comprising the same and the like.

Figure for publication: None